Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical formulations and use thereof in prevention of stroke, diabetes and/or congestive heart failure

A pharmaceutical preparation, diabetes technology, applied in the field of stroke prevention, diabetes and/or CHF, diabetes and/or congestive heart failure, prevention and/or treatment of stroke, can solve the problem of less prevention of cardiovascular diseases

Inactive Publication Date: 2002-12-11
SANOFI AVENTIS DEUT GMBH
View PDF15 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Said compounds are rarely used in the prevention of cardiovascular diseases, and the use of these compounds in the prevention of stroke, diabetes and / or CHF is so far unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0049] A large clinical trial was designed to examine the effect of the ACE inhibitor ramipril compared with placebo in reducing cardiovascular events.

[0050] Study conducted over 6 years at 267 centers in 19 countries with 9,541 participants at high risk of cardiovascular events due to previous history of ischemic heart disease, stroke, peripheral arterial disease or individuals with diabetes.

[0051] Patients participating in the study had a mean systolic blood pressure of 138 mm Hg, so these patients were normotensive at the start of the study. After one month of treatment with ramipril or placebo, systolic blood pressure decreased by 5.48 mm Hg and 1.59 mm Hg, respectively.

[0052] The primary objectives of the study were myocardial infarction (MI), stroke, and cardiovascular (CV) death (mortality).

[0053]The study was stopped early because there was a very significant reduction in cardiovascular death, heart attack and stroke among patients taking ramipril. In ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the production of renin-angiotensin system (RAS) inhibitors or pharmaceutically acceptable derivatives thereof, in particular ramipril or ramipril, for the prevention of stroke, diabetes and / or congestive heart failure. (CHF) in medicines. The present invention also relates to a method for preventing and / or treating stroke, diabetes and / or CHF, the method comprising administering a therapeutically effective amount of a RAS inhibitor or a pharmaceutically acceptable derivative thereof to a patient in need of said prevention and / or treatment, Specifically ramipril or ramipril.

Description

field of invention [0001] The present invention relates to the use of inhibitors of the renin-angiotensin system (RAS) or pharmaceutically acceptable derivatives thereof in the manufacture of medicaments for the prevention of stroke, diabetes and / or congestive heart failure (CHF). The present invention also relates to a method for preventing and / or treating stroke, diabetes and / or CHF, the method comprising administering a therapeutically effective amount of a RAS inhibitor or a pharmaceutically acceptable derivative thereof to a patient in need of said prevention and / or treatment. Background of the invention [0002] Compounds that interfere with the RAS are known in the art and are useful in the treatment of cardiovascular disease, especially hypertension and heart failure. RAS can be interfered mainly by inhibiting the enzyme that synthesizes angiotensin or by blocking the corresponding receptor at the effector site. Currently available are angiotensin-converting enzyme ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/00A61K31/357A61K31/401A61K31/4025A61K31/403A61K31/404A61K31/41A61K31/4166A61K31/4178A61K31/4184A61K31/435A61K31/497A61K31/519A61K31/55A61K31/551A61K31/554A61P3/10A61P9/02A61P9/04A61P9/10A61P43/00C07D209/52
CPCA61K31/403A61P25/28A61P3/00A61P3/10A61P43/00A61P7/12A61P9/00A61P9/02A61P9/04A61P9/08A61P9/10A61P9/12A61P9/14A61K31/40A61K31/41A61K31/4178A61K31/4184A61K31/519
Inventor B·肖勒肯斯N·本德B·兰古恩瓦拉G·达格奈斯H·杰斯坦恩A·勒琼格仁S·尤索夫
Owner SANOFI AVENTIS DEUT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com